Trial Profile
Clinical efficacy and genetic information in patients with refractory Takayasu arteritis treated with Tocilizumab,Infliximab or Ustekinumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jul 2017
Price :
$35
*
At a glance
- Drugs Infliximab (Primary) ; Tocilizumab (Primary) ; Ustekinumab (Primary)
- Indications Takayasu syndrome
- Focus Adverse reactions; Therapeutic Use
- 02 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism